This is a preview of subscription content, log in via an institution to check access.
Reference
Gordon SC, et al. Hepatitis C virus therapy is associated with lower health care costs not only in noncirrhotic patients but also in patients with end-stage liver disease. Alimentary Pharmacology and Therapeutics : 25 Aug 2013. Available from: URL: http://dx.doi.org/10.1111/apt.12454
Rights and permissions
About this article
Cite this article
Anti-HCV therapy: often deferred, but it can reduce costs. PharmacoEcon Outcomes News 687, 8 (2013). https://doi.org/10.1007/s40274-013-0726-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-013-0726-6